Seagen (SGEN) Osake Kurssi
Seagen Kurssi
Liikevaihto on kasvanut 36,0 % vuodessa viimeisten 19 vuoden aikana 2,30 Mrd. USD:een. Seagenn nettomarginaali on nyt −32,6 %, laskenut −6,9 %:sta muutama vuosi sitten.
Seagen osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Seagen liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Seagen -osakkeesta
Seagen Inc, formerly known as Seattle Genetics, operates under a unique business model focused on biotechnology. The company specializes in developing and commercializing innovative antibody-based therapies to treat cancer. By harnessing the power of antibody-drug conjugates (ADCs), Seagen Inc aims to deliver targeted treatments directly to cancer cells while minimizing damage to healthy cells. This approach allows for more effective and precise treatment options, potentially improving patient outcomes. Seagen Inc's commitment to research, development, and collaboration with partners worldwide demonstrates their dedication to advancing cancer care and providing hope for patients globally.
Seagen Inc is primarily active in the biotechnology industry.
The main competitors of Seagen Inc in the market include companies such as Genmab, AstraZeneca, and Roche.
Seagen Inc, formerly known as Seattle Genetics, is a biotechnology company based in Bothell, Washington. Established in 1997, Seagen focuses on the development and commercialization of innovative therapies for cancer treatment. The company has been at the forefront of antibody-drug conjugate (ADC) technology, which enables targeted delivery of potent drugs to cancer cells. Seagen's flagship product, ADCETRIS® (brentuximab vedotin), has gained significant recognition as a targeted therapy for Hodgkin lymphoma and certain types of non-Hodgkin lymphoma. With a commitment to advancing breakthrough therapies, Seagen continues to pave the way in the field of oncology.
Seagen Inc, a renowned biotechnology company, has achieved numerous significant milestones. Notably, the company received the US Food and Drug Administration (FDA) approval for its groundbreaking antibody-drug conjugate, ADCETRIS®. This therapeutic innovation has revolutionized the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Seagen Inc has also successfully introduced EVOTEC and SGEN-001, expanding its product portfolio and advancing the fight against cancer. The company's commitment to research and development has resulted in crucial advancements and collaborations, consolidating its position as a leader in the biopharmaceutical industry. Seagen Inc's relentless pursuit of innovative solutions continues to make a substantial impact in transforming patients' lives.
Seagen Inc, a leading biotechnology company, is primarily present in multiple countries and regions across the world. With its headquarters in the United States, Seagen Inc has a significant presence in North America, including the United States and Canada. Additionally, the company extends its operations and reach to various European countries, such as Germany, France, Italy, Spain, and the United Kingdom. Seagen Inc also has a presence in Asia, with a focus on Japan. Through its global presence, Seagen Inc is dedicated to advancing innovative therapies and improving patient outcomes worldwide.
Seagen Inc represents a set of core values and a corporate philosophy that drive its operations. The company places great emphasis on advancing science to develop innovative targeted therapies for patients facing cancer. With a focus on precision medicine, Seagen Inc strives to provide therapies that address significant unmet medical needs. By collaborating with partners, the company aims to advance its mission to make a meaningful difference in the lives of cancer patients. Seagen Inc's dedication to scientific excellence, patient-centricity, and collaboration forms the foundation of its corporate philosophy and guides its pursuit of breakthrough treatments in the field of oncology.
23 analyytikkoa arvioi tällä hetkellä Seagen-osaketta: 9 suosittaa ostoa, 14 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Seagen-yhtiöltä 5,33 Mrd. USD liikevaihtoa ja 3,70 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Seagen-osake noteerataan hintaan 204,33 EUR (228,74 USD).
Seagen-osake (SGEN) on listattuna 5 pörssissä, muun muassa: NASDAQ (SGEN), London (0A8R.L), SIX (Zürich) (SGT.SW), Frankfurt (SGT.F), München (SGT.MU).
Seagen Inc. is a biotechnology company specializing in the development of therapies for cancer and autoimmune diseases. The company was founded in 1998 and is headquartered in Seattle, USA. Seagen offers a wide range of products and services based on antibodies that can be used for the treatment of cancer and other serious diseases. The company operates in two main divisions: the commercial division and the clinical research and development division. The commercial division of Seagen currently distributes several approved products and therapies, including: - Adcetris: an antibody-drug conjugate (ADC) used for the treatment of lymphoma and Hodgkin's cancer. - Tukysa: an oral medication for the treatment of HER2-positive breast cancer. - Padcev: an ADC used for the treatment of bladder cancer. - Enfortumab Vedotin: an ADC used for the treatment of advanced urothelial carcinoma. - Seattle Genetics: a platform consisting of multiple antibody technologies used for the production of ADCs. Seagen's clinical research division is highly interested in developing new and innovative therapies for cancer and autoimmune diseases. One important area of research is new ADC products and antibody technologies that can help target cancer cells. Seagen pursues a comprehensive business model that includes the sale of new products and therapies, as well as collaborations with various pharmaceutical and biotech companies in the development of new technologies and therapies. The company has also entered into research collaborations with other companies and institutions to accelerate the discovery of new ADCs and other treatment options. In addition, Seagen also offers a range of services in the field of clinical studies, including planning, conducting, and analyzing studies. These services are offered to pharmaceutical and biotech companies developing their own products and technologies. Overall, Seagen aims to further expand its position as a leading provider of antibody-based therapies and products for cancer and autoimmune diseases. The company is committed to offering its customers and partners the best solutions and services to improve the treatment of patients worldwide. Answer: Seagen Inc. is a biotechnology company specializing in the development of therapies for cancer and autoimmune diseases. It offers a wide range of products and services for the treatment of cancer and other serious diseases, including antibody-drug conjugates (ADCs) such as Adcetris, Tukysa, Padcev, and Enfortumab Vedotin. Seagen is dedicated to developing new and innovative therapies, particularly in the field of ADC products and antibody technologies. The company operates in both commercial and clinical research divisions and collaborates with other organizations to accelerate the discovery of new treatment options. Additionally, Seagen provides services for clinical studies and aims to be a leading provider of antibody-based therapies worldwide.
odotettu liikevaihto Seagen on 5,33 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Seagen on 695,98 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Seagen:n hinta-voitto-suhde (P/E) on tällä hetkellä 61,83. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Seagen-osakkeen arvostusta.
Seagen:n hinta-myynti-suhde (P/S) on tällä hetkellä 8,08. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Seagen-osakkeen arvostuskennuslukuna.
Seagen:n Eulpool-laatuscore on 4/10.
Seagen:n ISIN on US81181C1045. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Seagen:n WKN on 602322. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Seagen:n ticker on SGEN. Tämä pörssinoteeraus käytetään Seagen-osakkeiden kauppaan pörssissä.
Seagen osake
Seagen vertaisryhmä
Seagen Ticker
Seagen FIGI
Kaikki tunnusluvut ja syvällinen analyysi Seagen:sta
Meidän osakeanalyysimme Seagen-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Seagen:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: